Introduction
There has been a slight reduction in the overall mortality from breast cancer; however, the prognosis for women with metastatic disease remains poor, with less than 10% survival at 5 years. 1 Patients with only bone metastases may represent a separate subgroup with an improved survival, although the prognosis in this group remains suboptimal. The majority of women with metastatic breast cancer will have bone involvement. 2 However, 20-25% of patients with metastatic breast cancer will have only bone involvement. Many patients with bone-only metastases are hormone-receptor positive, and the possibly more indolent course is the result of hormone-responsive disease and supportive care with bisphosphonates. In contrast, stage IV patients who are hormone-receptor negative or hormone refractory represent a more aggressive subgroup with at best a 10% 3-year progression-free survival (PFS). 2, 3 High-dose chemotherapy with hematopoietic support has demonstrated high objective response rates and some event-free survivors in women with metastatic breast cancer in a large number of phase II trials. [4] [5] [6] [7] The median survival in these studies ranged from 10-24 months, and the number of long-term survivors is 10-20%. The phase II studies led to a number of phase III randomized trials of high-dose chemotherapy in metastatic breast cancer patients. In an earlier study from Duke University, Peters et al. 8 reported a significant advantage in PFS with high-dose chemotherapy compared with observation in patients who achieved a complete remission after induction chemotherapy. The PEGASE 03 Study reported by Biron et al. showed a significant PFS and relapse rate advantage with high-dose chemotherapy compared to conventional anthracyclinebased chemotherapy for patients with metastatic disease; however, there was no overall survival (OS) advantage. 9 Similarly, the MA-16 Trial reported by Crump et al. 10 also showed a significant event-free survival (EFS) advantage with high dose compared to conventional chemotherapy but no difference in OS. The European Group for Blood and Marrow Transplantation reviewed their registry data for the past decade. 11 The large series corroborates the individual trials, with a suggestion of improved survival. In contrast, the PBT-1 Study reported by Stadmauer et al. 12 showed no differences in PFS or OS between high-dose chemotherapy with hematopoietic support compared with maintenance cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for women with metastatic breast cancer who responded to conventional induction chemotherapy. Patients with bone-only metastatic breast cancer have generally not been eligible for high-dose chemotherapy trials as they lack measurable disease and may have a different clinical course, so a study focused on this group was needed.
We performed a prospective, randomized phase III clinical trial of consolidation with high-dose chemotherapy and hematopoietic support versus observation with delayed high-dose chemotherapy in women with hormone-receptor negative or hormone refractory metastatic breast cancer confined to the bones.
Patients and methods

Enrollment
A total of 85 patients with metastatic breast cancer and only bone metastases were enrolled on the study at Duke University Medical Center and affiliated hospitals from 1992 to 1997. The protocol was Institutional Review Board approved. Informed consent was obtained from all patients.
Eligibility
The patients were at least 18 years old, had histologically confirmed metastatic breast cancer with only bone metastases, and had received no prior chemotherapy for metastatic disease. If the primary tumor was hormonereceptor positive, the patients were required to have failed at least one prior hormonal therapy before enrollment on study. The patients had a creatinine clearance X60 mls/min and SGOT, SGPT and bilirubin were within the normal range. The patients had an FVC, FEV1 and DLCO X60% of predicted, and a left ventricular ejection fraction X45% as determined by MUGA. The patients had a Karnofsky performance status of 80-100%. The patients were excluded from the protocol if they had metastatic breast cancer outside the skeleton, a history of another malignancy, co-morbid medical or psychiatric conditions that prevented high-dose chemotherapy with hematopoietic support, or if the patient was pregnant. Patients with bone marrow involvement were eligible.
Staging evaluation
Before protocol enrollment, the patients underwent CAT scans of the head, chest, abdomen and pelvis with bone windows, bilateral bone marrow aspirates and biopsies and a bone scan. The patients' characteristics, including age, hormone-receptor status, and number of involved bony sites, are summarized in Table 1 . followed by folinic acid rescue begun 24 h after the methotrexate and given at a dose of 15 mg orally every 6 h for six doses. The AFM chemotherapy was repeated every 3 weeks to a maximum of 4 cycles or the patient's cumulative doxorubicin dose would exceed 500 mg/m 2 at the end of cycles 2 or 3.
AFM induction chemotherapy
Randomization
Following the last cycle of AFM induction chemotherapy, the patients were restaged with computerized tomography (CT) scans of the head, chest, abdomen and pelvis, with bone windows; MUGA; pulmonary function tests (PFT's); and bilateral bone marrow aspirates and biopsies. The patients were randomized if they had no evidence of disease progression and met the eligibility criteria for high-dose chemotherapy with hematopoietic support.
Patients randomized to the observation arm received radiation therapy immediately as consolidation. The patients randomized to observation were followed carefully with an evaluation at 6 and 12 weeks post-randomization and every 12 weeks thereafter. Patients randomized to the high-dose chemotherapy arm were followed in an identical Note: Total patients in observation arm receiving anthracycline and nonanthracycline therapy is 37. Three patients received anthracycline-based therapy followed by non-anthracycline-based therapy. Abbreviation: HDC ¼ high-dose chemotherapy.
fashion and at the same intervals beginning 6 weeks post transplant. At each evaluation, the patients underwent CT scans of the chest, abdomen and pelvis with bone windows, in addition to routine physical examination and laboratory evaluation. A bone scan was repeated at the 12-week evaluation and every 12 weeks thereafter. The patients randomized to observation were offered high-dose chemotherapy with hematopoietic support at the time of progression.
High-dose chemotherapy and hematopoietic support All patients eligible for high-dose chemotherapy with hematopoietic support had peripheral blood progenitor cells collected following recovery from the last cycle of AFM chemotherapy. The patients were mobilized with granulocyte-colony stimulating factor (G-CSF) at 5 mg/kg/ day for a total of 5 consecutive days. Leukapheresis was performed using the Cobe Spectra and Version 5.0. The patients were leukapheresed on days 4, 5 and 6. At least 2 Â 10 6 CD34 cells/kg were collected from each patient and cryopreserved.
The high-dose chemotherapy was the STAMP 1 regimen.
14 The chemotherapy consisted of cyclophosphamide 1875 mg/m 2 /day, days À6 to À4; cisplatin 55 mg/m 2 /day continuous intravenous infusion days À6 to À4; and carmustine 600 mg/m 2 intravenously on day À3 immediately following completion of the cisplatin infusion. The patients received their autologous peripheral blood progenitor cells on days À1, 0 and þ 1. Reinfusion over 3 days was required due to the amount of dimethyl sulfoxide (DMSO) in the preserved product. The patients received G-CSF 5 mg/kg/day beginning on day À1 and continued through myeloid engraftment, as determined by an absolute neutrophil count (ANC) 41000/ml for 3 consecutive days.
Consolidative radiation therapy
Intensive consolidative radiation was given to sites of disease in both arms of therapy with the intent to maximize the opportunity for prolonged PFS. For patients randomized to observation, radiation therapy was administered 2-4 weeks following completion of AFM chemotherapy and peripheral blood progenitor cell leukapheresis. Patients randomized to immediate high-dose chemotherapy, consolidative radiation therapy was administered approximately 6 weeks following completion of high-dose chemotherapy after the patient had adequately recovered. For patients with evidence of progressive disease following high-dose chemotherapy, palliative radiation therapy was used. Patients were not treated with any hormonal therapy post transplant until the time of progression. Decisions regarding use of hormonal therapy after progression were left to the discretion of the treating physician. Data was not kept regarding use of, or number of hormonal therapies used, after progression.
Volume
An effort was made to irradiate all sites of bony disease identifiable before the initiation of AFM chemotherapy. In an effort to avoid severe hematologic toxicity, prescribed radiation fields were limited to include p30% of the bone marrow. For patients where radiation of all involved sites would exceed this limit, the most heavily involved sites, based on radiographs, were preferentially irradiated. Simultaneous irradiation of multiple sites was generally performed, particularly when irradiated volumes were small.
Dose
A dose of 44-50 Gy was delivered in 2 Gy fractions (five fractions per week, one treatment per day). The doses were modified depending on the clinical situation. In general, vertebral lesions received 44 Gy, while other bones received 50 Gy. Most patients received their consolidative radiation therapy at a facility other than Duke. However, in all cases, recommendations for radiation therapy were made in consultation with the radiation oncologists at Duke.
Response
The bone metastases were evaluated following each treatment phase, including the AFM induction chemotherapy, the high-dose chemotherapy with hematopoietic support, and following the consolidative radiation therapy. Extent of bone disease was characterized by number of lesions, not by location of lesions (see Table 1 ). A combination of bone scan and CAT scan with bone windows were the primary modalities to evaluate the bone metastases. 15 The use of magnetic resonance imaging (MRI) as a diagnostic modality for bone metastases was not well defined at the time this study was designed, nor was MRI readily available to all patients. A bone radiologist consistently evaluated the series of radiological studies, and he was blinded to the patient's randomization. Response was graded as stable or progression. Progressive disease was defined as new metastatic disease outside of the bones, a 425% increase in the lytic bone metastases or a new lytic bone metastasis seen on CT bone windows. The bone scan was not used as the determinant of progression, but helped the bone radiologist with the interpretation of the CT bone windows.
Statistical analysis
This trial was designed to be able to detect a doubling of the time to treatment failure in one of the arms or a 100% increase in survival of one of the treatment arms. Using a median months to failure of 8 and an entry rate of 12 patients per year, the study required enrollment of 35 patients per arm with an accrual duration of 5.8 years to complete the study. These estimates were based on a hazard ratio of 2 and with an 80% power to detect the differences.
The two end points considered were EFS and OS. Overall survival was measured from the time of randomization until death from any cause or censored at last follow-up. EFS was estimated from the time of randomization until an event occurred. An event was defined as death or disease progression. Patients who were alive and progression-free at the date of last follow-up were censored. The EFS endpoint from the time of transplant for the observation arm includes the interval from the first progression to a second progression, since most of the patients randomized to observation were transplanted only after a first progression.
The probability of EFS and OS were calculated by the Kaplan-Meier product limit method 16 and the Log-rank test was used to compare the two groups. The Cox proportional hazards regression analysis was also used to investigate the relationship between EFS, OS and the prognostic variables detailed below. Units of platelets and red blood cells transfused were analyzed as continuous variables, whereas all other variables were dichotomous.
Results
Patient enrollment and randomization
A total of 85 patients were entered into the study. Sixteen patients were not randomized due to a number of reasons: progressive disease on the AFM induction chemotherapy (n ¼ 8), patient refusal (n ¼ 3), psychotic depression (n ¼ 1), left ventricular ejection fraction o45% (n ¼ 1), angina and coronary artery disease (n ¼ 1), DLCO o60% of predicted (n ¼ 1), hepatic dysfunction with the SGOT 41.5 times normal (n ¼ 1). The remaining 69 patients were randomized according to the protocol; 34 patients were randomized to observation and 35 were randomized to immediate transplant.
Event-free survival
The median follow-up for the 69 randomized patients is 8.1 years from randomization. All 35 patients randomized to immediate high-dose chemotherapy received their scheduled treatment. The median EFS from randomization for the immediate transplant arm is 12 months. The 34 patients randomized to observation all progressed despite 32/34 (94%) having received consolidative radiation therapy. The median EFS from randomization for the observation arm is 4.3 months. The EFS Kaplan-Meier curves are shown in Figure 1 . The mean time to relapse from the date of randomization for the patients on the observation arm is 6 months. The Log-rank test indicates that there is a significant difference in EFS between the two arms, favoring immediate high-dose chemotherapy (Po0.0001, RR ¼ 4.23). Fewer immediate transplant patients received consolidative radiation therapy, 27/35 (77%) compared with the observation arm, 32/34 (94%), because of transplant-related toxicity. Twenty-seven of the 34 patients on the observation arm received high-dose chemotherapy with hematopoietic support following disease progression. Seven patients were not transplanted because of brain metastases or carcinomatous meningitis at the time of disease progression (n ¼ 4), patient refusal (n ¼ 1), rapid disease progression with extensive hepatic metastases and hepatic dysfunction (n ¼ 1) and one patient refused observation and had an immediate transplant at another institution. The median EFS from the time of transplantation for the 27 patients on the observation arm who received high-dose chemotherapy with hematopoietic support was 5 months. The difference in transplant failure-free survival from the time of randomization between the two arms is also statistically significant (P ¼ 0.0051) favoring the immediate transplant arm. The transplant was generally well tolerated whether the patient received an immediate transplant or transplant at the time of disease progression. There were no differences between the two groups with regards to infectious complications, veno-occlusive disease, interstitial pneumonitis or other toxicities, although the treatment numbers are relatively small.
Overall survival
The median OS for the patients on the immediate transplant arm was 2.97 years versus 1.81 years for the patients on the observation arm (P ¼ 0.144, RR ¼ 1.47). The OS Kaplan-Meier curves are shown in Figure 2 . Six patients (17%) randomized to the immediate transplant arm are still alive, including four progression-free survivors post transplant. Three patients (9%) randomized to observation are still alive including two progression-free survivors, and all three received transplant at the time of disease progression. One other patient progressed to AFM chemotherapy, and received high-dose melphalan with stem cell support, and remains alive 6.5 years later.
Of the entire group of 85 patients who were enrolled on the trial, 10 (12%) remain alive. All 10 patients received high-dose chemotherapy with hematopoietic support, nine received high-dose CPB on the Bone Only protocol, and the tenth received high-dose melphalan on another study.
Prognostic factors
Results of the Cox proportional hazards modelling indicate there were no significant differences in either EFS or OS when they were analyzed according to the following variables: days to ANC greater than 500, days to platelet recovery, number of sites of metastases, bone marrow biopsy histopathology (positive or negative), hormonereceptor status, adjuvant doxorubicin chemotherapy, adjuvant non-anthracycline chemotherapy, prior hormonal therapy and radiation therapy to bone before protocol enrollment. The two univariately significant variables were the number of units of platelets and red blood cells transfused, and these covariates were significantly associated with OS (P ¼ 0.013 and P ¼ 0.0009), respectively. The greater the number of units of platelets or red blood cells transfused predicted for a worse survival. This may reflect poor marrow reserves as a result of burden of disease in the marrow. The P-value and relative risk associated with each outcome is given in Table 2 .
Treatment-associated mortality
The overall transplant-related mortality (deaths occurring within 100 days after the initiation of high-dose chemotherapy) for all patients was 9.7%. A total of six patients died of toxicity rather than metastatic breast cancer, and all died in the acute post transplant phase. Of the six patients who died of toxicity, three were on the immediate transplant arm and three were on the observation arm with transplant at the time of disease progression. The specific causes of treatment-associated mortality were: three patients died of pneumonitis, two patients died of veno-occlusive disease of the liver, and one patient died of disseminated candidiasis. The mortality rate in this study is higher than that generally reported for similar trials. This is in part due to the toxic nature of the regimen, but may also be exaggerated by the small number of patients treated. There have been no cases of secondary myelodysplasia or leukemia and no late toxic deaths.
Discussion
We performed a phase III randomized trial comparing immediate high-dose chemotherapy with hematopoietic support versus observation with high-dose chemotherapy with hematopoietic support at the time of disease progression for women with metastatic breast cancer and only bone metastases. The statistical differences are apparent in EFS between the two treatment arms. It is difficult to interpret the OS data, because of the crossover strategy to high-dose chemotherapy at the time of disease progression for the patients randomized to observation. These patients are poor prognostic patients, so the majority relapse despite any therapy. In addition, the early deaths due to treatmentrelated mortality negatively impacted the OS in this relatively small randomized trial.
In addition to the small sample size this study is limited in other areas that have the potential to impact results. This study design utilized our induction chemotherapy regimen, which included an anthracycline. Some patients had received prior anthracycline in the adjuvant setting. For simplicity of study design we did not include alternative induction regimens in this setting. All patients who were hormone-receptor positive, or in whom this data was not known, were required to have failed one hormone therapy. We did not, however, require patients to fail sequential hormonal treatment before advancing to chemotherapy. Additionally the study did not require hormone-positive patients to be placed on hormonal therapy following progression after transplant, as treatment decisions at that point were left to the patient's primary oncologist. As we have previously stated, this regimen had an unacceptably high mortality rate.
There are three moderate-sized, randomized clinical trials investigating high-dose chemotherapy versus standard therapy for patients with metastatic breast cancer. 9, 10, 12 The PBT-1 study was a multi-center randomized trial of high-dose chemotherapy with hematopoietic support versus maintenance CMF chemotherapy for women with metastatic breast cancer. 12 The PBT-1 study showed no differences in the PFS or OS between the two treatment arms. The results from this study are difficult to interpret because of the poor survival results in both treatment results. A total of 553 patients were enrolled on the trial, 199 were randomized and only 184 were eligible and treated according to their randomized arm. Less than 10 patients in each arm had only bone metastases. The median survival between the two groups was not different, 24 months in the high-dose chemotherapy versus 26 months for the conventional CMF arm. There was also no difference in the time to progression; 9.6 months for the high-dose chemotherapy arm and 9.0 months for the conventional chemotherapy arm. The 3-year PFS was only 6% for the high-dose chemotherapy arm and 12% for the CMF arm.
The second reasonably sized randomized trial was the Canadian MA-16 trial; 379 patients were enrolled over a 3.5 year period. 10 A total of 224 patients were randomized, with the majority not randomized because of unresponsive disease to standard chemotherapy. Patients received four cycles of an anthracycline-based regimen if the patient had no prior anthracycline chemotherapy or a taxane if the patient had received prior adjuvant anthracycline. Patients who were hormone-receptor positive were not required to have failed hormonal therapy to be eligible for the MA-16 trial. The patients were randomized to two additional cycles of their induction chemotherapy followed by leukapheresis and high-dose chemotherapy versus continuation of the same standard chemotherapy to a total of nine cycles of chemotherapy. Fifty-eight per cent of the patients had bone metastases in the MA-16 trial, and approximately 20% with bone-only metastases. The OS is not different between the high-dose chemotherapy arm and the standard chemotherapy arm (P ¼ 0.9). However, the PFS is improved in the high-dose chemotherapy arm (P ¼ 0.0143).
The third randomized trial of high-dose chemotherapy versus standard therapy was the French PEGASE 03 trial. 9 The PEGASE trial is relatively small with 308 patients enrolled, of whom 180 patients responded to induction FEC chemotherapy and were eligible for randomization. The patients were randomized to four more cycles of FEC or high-dose chemotherapy with hematopoietic support. Similar to the MA-16 trial, the disease-free survival was improved in the high-dose chemotherapy arm; 46 versus 19% in the standard therapy arm at 1 year (P ¼ 0.0001). However, the 3-year OS was not improved; 38% in the high-dose chemotherapy arm versus 30% in the standard chemotherapy arm (P ¼ 0.7).
The high-dose chemotherapy regimens used in the four trials were quite different. The Duke Bone Only Protocol used high-dose cyclophosphamide, cisplatin and BCNU. The PBT-1 trial used continuous infusion cyclophosphamide, carboplatin and thiotepa. The MA-16 trial used cyclophosphamide, mitoxantrone and carboplatin. In the PEGASE trial, high-dose cyclophosphamide and thiotepa were used. We have demonstrated that the high-dose chemotherapy schedules and pharmacokinetics are important and predict for survival. 17 The use of thiotepa inhibits the conversion of cyclophosphamide to its active form 4-hydroperoxycyclophosphamide, thus, potentially decreasing the efficacy of the thiotepa-based regimens.
The analysis by Berry et al. 18 comparing the CALGB trials with the American Bone Marrow Transplant Registry data for similar patients with untreated metastatic breast cancer provides an interesting observation that early survival is not changed with high-dose chemotherapy, but the long-term survival may be prolonged. In every subgroup in the comparison analysis, except those patients who were complete responders to induction chemotherapy, high-dose chemotherapy with hematopoietic support resulted in a statistically significant improvement in the number of long-term survivors.
In summary, our randomized trial of high-dose chemotherapy versus observation in women with bone-only metastases demonstrates a significant improvement in the EFS, with no difference in OS. Event-free survival has clinical importance for patients in the setting of treatments that do not provide toxic outcomes that may affect quality of life. Many of the patients who progressed following observation were able to receive high-dose chemotherapy with hematopoietic support and some were converted to long-term, progression-free survivors. This trial demonstrates that some people with metastatic breast cancer and bone-only metastases can be long-term, progression-free survivors. Although mixed-outcomes in the use of highdose chemotherapy for metastatic breast cancer have been reported, there are some data suggesting that some patients derive benefit from this therapeutic approach. Since the design and conduct of this trial, many effective therapeutic agents have been introduced. The use of these agents, hormonal, cytotoxic, immunological, and supportive, may provide further improvement in both EFS and OS in the post transplant patient.
